International Experts Commend Riyadh’s Lifestyle Transformation Projects
5.5.2019 15:08:00 EEST | Business Wire | Press release
A panel of prominent International experts from various academic and professional fields convened yesterday to discuss Riyadh’s USD23 billion investment in the recently announced 4 Grand Projects that will transform the city and improve the wellbeing of millions of citizens in the capital city.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190505005026/en/
Group picture of the international experts attending Riyadh’s Lifestyle Transformation Forum (Photo: AETOSWire)
The Subject Matter Expert (SME) Forum took place at the Exhibition Centre King Fahad Library Plaza on 1st and 2nd May 2019. Discussion centered on a number of topics, including sustainable urban development, conservation, socio-economic well-being, art and culture, and the facilitation of a healthy lifestyle for all citizens.
The 4 Wellbeing Projects will greatly improve Saudis’ way of life by providing a greener, healthier environment and by encouraging participation in cultural and sporting life, in line with the Kingdom’s Vision 2030. These four projects are part of a massive development plan for the capital Riyadh, highlighting the Kingdom's leadership in sustainable urbanization and environmental management.
The Projects are: King Salman Park – one of the world’s largest urban parks with a land area of 13 km2, roughly four times that of Central Park in New York. The park, in addition to its large green spaces, will include a national theatre, opera house and art academy, and will host entertainment, environmental and cultural events. Green Riyadh – an urban greening project that will reduce CO2 levels and cool the city by up to 2°C. Green Riyadh will see 7.5 million trees planted in gardens, parks, mosques, schools and around the capital’s governmental and health sectors. Riyadh Art – a citywide gallery that will include 1,000 works of art and interactive installations, placed in residential areas, public parks, transport facilities and on Riyadh’s roads. Sports Boulevard – the first of its kind in the region, will feature 135 km of multi-purpose track for walking, running, cycling and horse riding.
“What I’ve seen over these two days is very much at the cutting edge and redefines what a city could be. What Riyadh is doing here I haven’t seen anywhere else in the world – where the planning is so integrated and well thought through, and innovative thinking is so evident. Riyadh is setting the standard. I commend these 4 Grand Projects,” John Rossant, Chairman & Founder, New Cities Foundation.
“Every one of these Wellbeing Projects is quite extraordinary. Riyadh will be transformed in ways that you and I can’t fully understand. They will transform this city not just in its infrastructure and facilities, but will transform health, culture and the very way citizens live their lives,” said Dr. David Griggs, Professor, Sustainable Development Institute, Monash University.
“The scale of these city projects is really impressive. Planting a few trees is nice. Maybe planting a couple of blocks is worthy. But it’s only when you get to the scale of 7.5 million trees and 9% green coverage of the city that you can actually change the climate and cool the city down,” John Englander, Oceanographer & Author, commenting on the 7.5 million trees that will be planted as part of the Riyadh Green Project.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190505005026/en/
Contact information
Riyadh Development Authority
Riyadh, Kingdom of Saudi Arabia
Arch.
Khalid Al-Hazani, Director, Architectural Projects Program & Public
Affairs
+966544777772, hazzani@ada.gov.sa
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
